Sergio Iannazzo

Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.

Roberto W. Dal Negro, Lorenzo Pradelli, Silvia Tognella et al. · PubMed · 2011 · 35 citations

Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update

Roberto W. Dal Negro, Luca Bonadiman, Paola Turco et al. · ClinicoEconomics and Outcomes Research · 2015 · 32 citations · Full text

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.

Negro Roberto Dal, M Eandi, Lorenzo Pradelli et al. · PubMed · 2007 · 30 citations

Asthma, Severe Copd Patients, Pulmonary Care +17

Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A

Sergio Iannazzo, Paolo Angelo Cortesi, Roberto Crea et al. · Blood Coagulation & Fibrinolysis · 2016 · 24 citations

Cost-effectiveness Analysis, Pharmacotherapy, Thrombosis +17

Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy

Mario Eandi, Lorenzo Pradelli, Sergio Iannazzo et al. · PharmacoEconomics · 2010 · 23 citations

Secondary Hyperparathyroidism, Parathyroid Hormone, Parathyroid Disease +3